FDA LISTING INC: EXPERIENCED ADVISORS FOR FULL-SERVICE FDA REGISTRATION & COMPLIANCE
+1 212 444 8202
FDA Antifungal Monograph M005 outlines conditions that may apply to over-the-counter topical antifungal drug products marketed in the United States, including permitted active ingredients, concentration ranges, labeling, directions, warnings, and related compliance requirements.
Topical antifungal products are OTC drug products intended to treat certain superficial fungal skin infections. FDA Monograph M005 covers certain topical antifungal products, including creams, ointments, lotions, powders, sprays, solutions, and similar topical dosage forms.
For brand owners, importers, private-label companies, and manufacturers, key compliance considerations include the active ingredient and concentration, intended use, dosage form, Drug Facts labeling, required warnings, directions for use, and FDA drug establishment registration and drug-listing requirements.
FDA Monograph M005 may apply to athlete’s-foot creams, powders, sprays, and solutions; jock-itch products; ringworm treatments; topical clotrimazole products; topical miconazole products; tolnaftate products; and certain undecylenic acid or undecylenate products. The product format alone does not determine whether a product fits the monograph. Also review the active ingredient, concentration, intended use, dosage form, directions for use, warning statements, and labeling claims. A product’s claims should match the applicable active ingredient conditions and the finished formulation.
Products marketed for nail fungus, scalp fungus, systemic fungal infections, yeast infections, oral thrush, vaginal yeast infections, fungal diaper rash, or other fungal conditions may fall under a different FDA regulatory framework. A topical antifungal product should not make claims that exceed its applicable M005 conditions. Diaper-rash treatment is not a general M005 topical-antifungal indication. Products intended for fungal diaper rash should not be assumed to fit the standard M005 conditions and require separate regulatory review.
| Active Ingredient | Concentration Range | Common Product Terms |
|---|---|---|
| Clotrimazole | 1% | Clotrimazole cream, athlete’s-foot cream, ringworm treatment |
| Miconazole nitrate | 2% | Miconazole cream, jock-itch cream, antifungal cream |
| Tolnaftate | 1% | Tolnaftate powder, athlete’s-foot spray, antifungal cream |
| Undecylenic acid | 10% to 25% total undecylenate concentration | Undecylenic acid solution, athlete’s-foot treatment |
| Calcium undecylenate | 10% to 25% total undecylenate concentration | Antifungal powder, athlete’s-foot product |
| Copper undecylenate | 10% to 25% total undecylenate concentration | Antifungal cream, topical antifungal product |
| Zinc undecylenate | 10% to 25% total undecylenate concentration | Antifungal powder, athlete’s-foot powder |
| Povidone-iodine | 10% | Topical antifungal solution, antifungal product |
| Clioquinol | 3% | Topical antifungal cream, antifungal treatment |
| Haloprogin | 1% | Topical antifungal product |
FDA Monograph M005 includes active ingredients, concentration conditions, dosage-form limitations, and labeling requirements that may differ by product use. This table provides a simplified overview of common topical antifungal ingredients and does not replace a review of the complete monograph.
Review topical antifungal labeling as part of the finished product’s overall compliance position. Active ingredients, concentration, intended use, dosage form, Drug Facts content, warnings, directions, principal display panel statements, and online marketing should align with the product’s applicable conditions.
Antifungal claims should match the active ingredient, concentration, intended use, and finished product dosage form. Products covered by M005 may be marketed for the treatment of athlete’s foot, jock itch, and ringworm.
A product should not use broader claims for nail fungus, toenail fungus, scalp fungus, systemic fungal infections, vaginal yeast infections, fungal diaper rash, or other conditions outside the applicable topical-antifungal monograph conditions. Claims on packaging, ecommerce listings, retailer descriptions, websites, social media, and advertising should remain consistent with the Drug Facts panel.
The Drug Facts panel should identify each active ingredient and its concentration, together with the corresponding purpose. The product name, front-label claims, and terms such as “antifungal,” “athlete’s foot,” “jock itch,” or “ringworm treatment” should match the product’s active ingredient and permitted intended use.
If a topical antifungal product contains more than one active ingredient, review the formulation and labeling for applicable combination conditions. Do not assume that separately permitted antifungal active ingredients can be combined in any concentration, dosage form, or claim combination.
Topical antifungal products generally require product-specific warning statements and directions. Depending on the active ingredient and intended use, warnings may address external use only, avoiding contact with eyes, avoiding use on the scalp or nails, discontinuing use if irritation occurs, and consulting a doctor if the condition persists or worsens. For products containing M005 antifungal active ingredients, labeling should include: “Do not use on children under 2 years of age unless directed by a doctor.”
Directions should match the active ingredient, product type, dosage form, frequency of use, and applicable age group. Products intended for athlete’s foot or ringworm are generally used daily for four weeks, while products intended for jock itch are generally used daily for two weeks. The finished product’s Drug Facts panel should include the applicable directions and duration of use.
Topical antifungal products should include appropriate Drug Facts information, including active ingredients, purpose, uses, warnings, directions, and inactive ingredients. The Drug Facts panel should correspond to the finished product that is commercially distributed.
Review product names, athlete’s-foot claims, jock-itch claims, ringworm claims, website content, retailer product descriptions, and advertising for consistency with the Drug Facts panel. Claims on ecommerce listings, social media, and other marketing materials should not expand the product’s permitted intended use.
This page provides a simplified overview of FDA OTC Monograph M005. It does not include every active ingredient, concentration range, permitted combination, dosage-form requirement, testing requirement, labeling detail, warning, direction, or FDA administrative order that may apply to a specific topical antifungal product.
For complete and current requirements, including active-ingredient conditions and administrative orders applicable to OTC topical antifungal drug products, review the related official FDA monograph resource.
We assist with:
Need help with an FDA-regulated topical antifungal product? Our team can assist with Drug Establishment Registration, OTC Drug Listing, NDC Labeler Codes, OTC Drug Label Review, and Drug Master Files.
_______ Related Services _______
_______ Related Services _______